Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 23:11:553626.
doi: 10.3389/fneur.2020.553626. eCollection 2020.

Determinants of Quality of Life in Myasthenia Gravis Patients

Affiliations

Determinants of Quality of Life in Myasthenia Gravis Patients

Piotr Szczudlik et al. Front Neurol. .

Abstract

Background: Although approximately half of myasthenia gravis (MG) patents achieve remission, for the remaining group MG is often a life-long disease. Better understanding of the determinants of Quality of Life (QoL) in MG is needed to optimize treatment goals in chronic cases. Materials and Methods: We performed a single center cross-sectional study in 339 MG adult patients (64.9% women), with ocular or generalized disease. SF-36 and a structured questionnaire was administered, including information on previous and current MG severity, medications, comorbidities, education, occupation and BMI of the patient. Mean disease duration was 7.5 + 9.3 years. Current age was 51.6 + 18.3 years, 55% had Early-Onset (<50 years) MG. Results: There were no statistically significant differences in mean SF-36 subscores between women and men. Worse MGFA class was related to lower QoL in physical (PCS) and mental (MCS) subscore (p = 0.000 for both). Patients with MGFA I-II class had significantly better QoL in physical and mental subscores than patients with more severe MG (p < 0.005). Late-onset MG patients had worse QoL than EOMG in physical score domain PCS (p = 0.049). Overweight and obese patients had lower PCS (p = 0.002) and MCS (p = 0.038) than patients with normal BMI. University education was related to statistically higher PCS (p = 0.015) and MCS (p = 0.006). QoL in currently employed was better in PCS and MCS (p = 0.000), with white collar workers reporting higher PCS (p = 0.049) than the remaining group. Patients living with family evaluated their MCS (p = 0.015) better than living alone. Moderate physical activity (twice a week) improved PCS (p = 0.045). Conclusion: Our study confirmed that greater severity of symptoms, age, age of onset but also BMI, type of work, education status and physical activity affect QoL in MG.

Keywords: MGFA; SF-36; employment; myasthenia gravis; obesity; quality of life.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The influence of MGFA score on QoL assessment. *P < 0.05. In PCS there were significant differences between patients in remission and MGFA II or more, between MGFA I and III or more, MGFA II and III or more; in MCS significant differences were found between patients in remission and MGFA II and more.
Figure 2
Figure 2
QoL assessment in PCS and MCS domain depending on BMI grouped by gender; *P < 0.05. BMI, body mass index; BMI (N), BMI up to 25 kg/m2.
Figure 3
Figure 3
QoL assessment in PCS and MCS domain depending on employment status; *P < 0.05.

References

    1. McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. (2010) 34:171–83. 10.1159/000279334 - DOI - PubMed
    1. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Preval. Clin. Correl. Diagn. Value Neurol. (1976) 26:1054–9. 10.1212/WNL.26.11.1054 - DOI - PubMed
    1. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. (2001) 7:365–8. 10.1038/85520 - DOI - PubMed
    1. Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, et al. . A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. (2014) 52:139–45. 10.1016/j.jaut.2013.12.004 - DOI - PubMed
    1. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. (2001) 357:2122–8. 10.1016/S0140-6736(00)05186-2 - DOI - PubMed

LinkOut - more resources